US 2020/0246423 Al  48  Aug. 6, 2020  TABLE 1.2-continued  TABLE 1.2  TABLE 1.3  Form  No  1.3-1  1.3-2  1.3-3  His  Sucrose  NaCl  KC!  pH  (mM)  (w/v %)  (mM)  (mM)  CaC12  (mM)  MgC12  PS 80  HSA  (mM)  (%)  (%)  6.0  6.0  6.0  0  0  4  40  40  40  5  0  5  0  0  0  0  0.03  0.1  0.1  0  PS80,  Form  Histdine  optioanlly  Sucrose  #  (mM)  (%w/v)  (%w/v)  1.2-1  0  0.01  4  1.2-2  0  0.01  4  NaCl  (mM)  pH  40  6  80  6  Stabilizer  Null  Captisol  Form  #  1.2-3  1.2-4  1.2-5  1.2-6  1.2-7  1.2-8  1.2-9  1.2-10  1.2-11  1.2-12  1.2-13  1.2-14  1.2-15  1.2-16  1.2-17  1.2-18  1.2-19  1.2-20  1.2-21  1.2-22  1.2-23  1.2-24  1.2-25  1.2-26  1.2-27  1.2-28  1.2-29  1.2-30  1.2-31  1.2-32  1.2-33  1.2-34  1.2-35  Histdine  (mM)  0  4  4  4  4  0  0  0  0  0  0  0  0  4  0  0  4  4  0  0  4  2  4  4  4  4  4  0  0  4  4  0  0  PS80,  optioanlly  (%w/v)  0.02  0.02  0.01  0.02  0.01  0.02  0.02  0.02  0.01  0.01  0.02  0.02  0.01  0.01  0.02  0.01  0.01  0.01  0.01  0.01  0.02  O.G15  0.02  0.02  0.01  0.01  0.02  0.01  0.02  0.02  0.02  0.02  0.02  Sucrose NaCl  (% w/v) (mM)  pH Stabilizer  5  5  5  4  5  5  4  4  5  4  5  5  5  4  4  5  5  5  5  4  4  4.5  4  5  5  4  5  4  5  4  4  4  5  40  5.7  Captisol  80  6  CaC12  40  6  Captisol  80  6  Null  40  5.7  CaC12  80  6  HP-beta-CD  80  5. 7  Captisol  40  6  Captisol  80  6  Null  80  5.7  Null  40  6  Null  80  6  Captisol  40  5.7  Captisol  80  6  CaC12  40  5.7  Null  80  5.7  HSA  40  5.7  Null  80  5. 7  Captisol  40  6  CaC12  40  5.7  CaC12  40  6  HP-beta-CD  60  5.85 HP-beta-CD  40  6  CaC12  40  5.7  Captisol  40  6  HP-beta-CD  40  5.7  Captisol  80  5.7  HP-beta-CD  80  5.7  HP-beta-CD  40  5.7  HP-beta-CD  80  5.7  CaC12  80  6  80  6  Captisol  CaC12  80  5.7  Null  [0247]  In a further embodiment, exemplary aflibercept  formulations are listed in Table 1.3 below. Formulations in  Table 1.3 include formulations that are buffer free, organic  co-solvent free, and buffer-free and organic co-solvent-free.  All formulations Table 1.3 contain 40 mg/mL aflibercept.  [0246]  In one embodiment, stable formulations comprise  aflibercept and low concentration of specific salts ( calcium  chloride, magnesium chloride and potassium chloride)  within the range present in human vitreous humor. In a  further embodiment, the formulation comprises a stabilizer  such as a sugar (e.g. sucrose) or Human Serum Albumin  (e.g. recombinant HAS). In another embodiment, the for› mulation is free of an organic co-solvent. The use of rHSA  is the most common protein found in human plasma and is  known for ligand binding and colloidal stabilization, prop› erties that are also ideal for the stabilization of proteins and  other biologics. In addition, because rHSA is a natural  protein in the body, it is safer than alternative surfactant  excipients, such as synthetic polymers, because it has a low  risk for immunogenicity and there is a natural pathway for  its elimination from the body.  [0245]  In a further embodiment, exemplary aflibercept  formulations are listed in Table 1.2 below. A surfactant ( e.g.  polysorbate 80) is optionally included in the formulations of  table 1.2. Formulations in Table 1.2 include formulations  that are buffer free, organic co-solvent free, and buffer-free  and organic co-solvent-free All formulations Table 1.2 con› tain 40 mg/mL aflibercept. In one embodiment, Captisol, if  present in the formulation, is present at about 0.1 % to about  2% w/v. In another embodiment, CaC1$_{2}$ ,  if present in the  formulation, is present at about 1 to about 10 mM. In still  another  embodiment,  hydroxypropyl-beta-cyclodextrin  (HP-beta-CD), if present in the formulation, is present at  about 0.1 % to about 2% w/v. In another embodiment, human  serum albumin (HSA), if present in the formulation, is  present at about 0.01 % to about 2% w/v.  about 1 mM to about 3 mM, about 1 mM to about 2 mM,  about 2 mM to about 5 mM, about 2 mM to about 4 mM,  about 2 mM to about 3 mM, about 3 mM to about 5 mM,  about 3 mM to about 4 mM, or about 4 mM to about 5 mM)  calcium ion (e.g., provided as calcium chloride); about 0.1  mM to about 5 mM (e.g., about 0.1 mM to about 4 mM,  about 0.1 mM to about 3 mM, about 0.1 mM to about 2 mM,  about 0.1 mM to about 1 mM, about 0.1 mM to about 1 mM,  about 0.5 mM to about 5 mM, about 0.5 mM to about 4 mM,  about 0.5 mM to about 3 mM, about 0.5 mM to about 2 mM,  about 0.5 mM to about 1 mM, about 1 mM to about 5 mM,  about 1 mM to about 4 mM, about 1 mM to about 3 mM,  about 1 mM to about 2 mM, about 2 mM to about 5 mM,  about 2 mM to about 4 mM, about 2 mM to about 3 mM,  about 3 mM to about 5 mM, about 3 mM to about 4 mM, or  about 4 mM to about 5 mM) magnesium ion ( e.g., provided  as magnesium chloride); about 0.1 mM to about 10 mM  (e.g., about 0.1 mM to about 8 mM, about 0.1 mM to about  6 mM, about 0.1 mMto about4 mM, about 0.1 mMto about  2 mM, about 0.1 mM to about 1 mM, about 0.1 mM to about  0.5 mM, about 0.5 mM to about 10 mM, about 0.5 mM to  about 8 mM, about 0.5 mM to about 6 mM, about 0.5 mM  to about 4 mM, about 0.5 mM to about 2 mM, about 0.5 mM  to about 1 mM, about 1 mM to about 10 mM, about 1 mM  to about 8 mM, about 1 mM to about 6 mM, about 1 mM to  about 4 mM, about 1 mM to about 2 mM, about 2 mM to  about 10 mM, about 2 mM to about 8 mM, about 2 mM to  about 6 mM, about 2 mM to about 4 mM, about 4 mM to  about 10 mM, about 4 mM to about 8 mM, about 4 mM to  about 6 mM, about 6 mM to about 10 mM, about 6 mM to  about 8 mM, or about 8 mM to about 10 mM) of a buffer  (e.g., histidine or imidazole) having a pH of about 5.5 to  about 6.2 (e.g., about 6.0). 